GO
Loading...

Sanofi SA

More

  • March 23- Pfizer Inc and Eli Lilly and Co will resume a late-stage study testing their pain drug tanezumab after the U.S. Food and Drug Administration lifted a partial hold on it. Pfizer expects to receive a $200 million upfront payment from Lilly as a result of the development, the companies said on Monday. In 2013, Pfizer forged a deal with Lilly to jointly develop...

  • *Up from three potential $1 billion- plus drugs in 2014. LONDON, March 23- Bristol-Myers Squibb, Sanofi and Novartis have the three top new drugs set to reach the market in 2015, among 11 products each with $1 billion- plus sales potential, according to a Thomson Reuters analysis. In total, 11 of the many new drugs set for launch in 2015 are expected to generate $1 billion-...

  • *Up from three potential $1 billion- plus drugs in 2014. LONDON, March 23- Bristol-Myers Squibb, Sanofi and Novartis have the three top new drugs set to reach the market in 2015, among 11 products each with $1 billion- plus sales potential, according to a Thomson Reuters analysis. In total, 11 of the many new drugs set for launch in 2015 are expected to generate $1 billion-...

  • PARIS, March 19- Sanofi's lixisenatide drug for the treatment of type 2 diabetes does not increase cardiovascular risk among high risk patients, the French drugmaker said on Thursday. Sanofi was reporting the results of a study it has been waiting to complete before seeking U.S. approval. At the time Sanofi said it would re-submit a U.S. new drug application with...

  • LONDON, March 17- Other big drugmakers may be reshaping their businesses but Novo Nordisk's focus on diabetes will get even bigger in the coming decade, according to the man most likely to be the Danish company's next boss. Kaare Schultz, who was made deputy chief executive in January 2014 and is the frontrunner to eventually succeed 60- year-old Lars Sorensen,...

  • An analysis of about 4,500 patients who stayed on treatment for nearly a year after completing earlier trials of Amgen Inc's Repatha, also known as evolocumab, found that 0.95 percent of those given the drug and standard therapy suffered a cardiovascular event, compared with 2.18 percent of the group on standard treatment, which ranged from diet changes to...

  • An analysis of about 4,500 patients who continued treatment for nearly a year after completing earlier trials of Amgen Inc's Repatha, also known as evolocumab, found that 0.95 percent of patients given the drug and standard therapy suffered a cardiovascular event, compared with 2.18 percent of the group receiving standard treatment, which ranged from...

  • LONDON, March 14- Long-term use of AstraZeneca's drug Brilinta can cut the risk of death, another heart attack or stroke in patients with a history of past attacks by 16 percent, a keenly awaited clinical trial showed on Saturday. The finding may boost sales of the blood-thinner, which AstraZeneca is relying on to drive growth, although doctors must balance its...

  • LONDON, March 12- Pfizer is seeking new vaccine opportunities across the age spectrum as it broadens its portfolio by delivering shots into the arms of adolescents and the elderly, as well as infants. For many years the vaccines industry has been dominated by five big companies, but that has shrunk to four with GlaxoSmithKline's purchase of Novartis' business.

  • Arrowhead buys Novartis' RNAi portfolio Thursday, 5 Mar 2015 | 7:34 AM ET

    March 5- Arrowhead Research Corp said it acquired Novartis AG's RNAi assets to fortify its position in the field of gene therapy that aims to wipe out disease-causing proteins. Novartis is eligible to receive $25 million in Arrowhead shares within 30 days, which would make it the second-largest shareholder based on Arrowhead's market value on Wednesday.

  • Fighting mosquitoes with more mosquitoes Wednesday, 4 Mar 2015 | 12:09 PM ET
    Mosquito Dengue Fever

    Constant vigilance is the method the Florida Keys has used to ward off mosquito-borne illnesses, but new methods may be on the horizon.

  • Sacked Sanofi boss joins PureTech board Friday, 27 Feb 2015 | 10:08 AM ET

    PARIS, Feb 27- Chris Viehbacher, sacked as chief executive of French drugs firm Sanofi last year, is to join the board of PureTech, a privately owned healthcare science and technology R&D company. Viehbacher, who moved to Boston last year while he was still running Sanofi, raised the French company's multinational profile during his six years in the job by...

  • Feb 26- Sanofi's new Toujeo diabetes drug has won U.S. regulatory approval but with wording on its label that analysts say could make marketing difficult. Sanofi shares were 1 percent lower at 88.20 euros by 1029 GMT. Sanofi bought some time with a patent infringement lawsuit filed last year against Eli Lilly and Co to keep a cheaper Lantus generic off the market...

  • Feb 23- Eli Lilly and Co said it would postpone by at least two years the marketing application for its once-daily diabetes treatment to evaluate liver concerns, a delay some analysts said could doom the experimental drug. In the meantime, Lilly continues to develop a cheaper, rival "biosimilar" form of Sanofi's blockbuster once-daily Lantus insulin that...

  • PARIS, Feb 23- French pharmaceuticals group Sanofi came under fire from French government ministers on Monday over a welcome bonus planned for its new CEO. Sanofi's new boss, Olivier Brandicourt could pocket a one-off golden handshake of 4 million euros in addition to making 4.2 million euros a year. Executive pay is frequently a touchy subject in egalitarian...

  • NEW YORK/ FRANKFURT, Feb 20- Warren Buffett's Berkshire Hathaway Inc said on Friday it had agreed to buy German motorcycle apparel and accessories retailer Detlev Louis Motorrad-Vertriebs GmbH for a little more than 400 million euros. The purchase enables Buffett, known for his optimism about the United States and the investment opportunities it offers, to...

  • PARIS, Feb 20- Sanofi's new boss Olivier Brandicourt could earn up to 4.2 million euros a year at the drugs group and pocket an extra 4 million euros within 12 months as a one-off golden handshake. Brandicourt will also get 220,000 stock options and 45,000 performance shares a year in Sanofi, matching Viehbacher's award. He has a higher cash earnings potential...

  • New Sanofi boss will earn up to 4.2 mln eur a year Friday, 20 Feb 2015 | 1:36 PM ET

    PARIS, Feb 20- Sanofi's new boss Olivier Brandicourt will earn up to 4.2 million euros a year at the drugs group and could pocket 4 million extra as a one-off golden handshake. The pay of the former medical doctor, who is due to take up his new role from April, was revealed in a statement by the French drugs firm on Friday, a day after the 59- year-old Bayer AG executive was...

  • Early movers: DE, ABBV, WMT, DSW, YHOO & more Friday, 20 Feb 2015 | 7:54 AM ET
    A trader works on the floor of the New York Stock Exchange.

    Some of the names on the move ahead of the open.

  • PARIS, Feb 19- French drugmaker Sanofi on Thursday named Olivier Brandicourt, a Paris- educated doctor and head of Bayer AG's healthcare arm, as its chief executive officer. Brandicourt had been widely tipped to become Sanofi's new boss, a position that opened when Chris Viehbacher was suddenly sacked last year. "Olivier Brandicourt's strong experience...